Results 11 to 20 of about 1,086,070 (250)

Europe's contribution to the evaluation of the use of systemic antimicrobials in the treatment of periodontitis

Periodontology 2000, EarlyView., 2023
Abstract This narrative review celebrates Europe's contribution to the current knowledge on systemically administered antimicrobials in periodontal treatment. Periodontitis is the most frequent chronic noncommunicable human disease. It is caused by dysbiotic bacterial biofilms and is commonly treated with subgingival instrumentation.
David Herrera, Arie Jan van Winkelhoff, Paula Matesanz, Katalina Lauwens, Wim Teughels   +4 more
wiley   +1 more source

Prevalence of multidrug-resistant tuberculosis in East Africa: A systematic review and meta-analysis.

PLoS ONE, 2022
BackgroundThe rate of multidrug-resistant tuberculosis is increasing at an alarming rate throughout the world. It is becoming an emerging public health problem in East Africa.
Kindu Alem Molla, Melese Abate Reta, Yonas Yimam Ayene   +2 more
doaj   +1 more source

Multidrug-resistant tuberculosis in middle ear: A case report

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2023
Background: Tuberculosis (TB) continues to be a common disease in developing countries, among which middle ear TB is rare. Furthermore, it is relatively difficult to make an early diagnosis and provide follow-up treatment for middle ear TB.
Tanze Cao, Xiuping Liu, Chengqing Yang, Chunlin Mei, Jiali Ou, Ronghui Du   +5 more
doaj   +1 more source

An update on multidrug-resistant tuberculosis [PDF]

Clinical Medicine, 2019
Of the 10 million incident cases of tuberculosis (TB) globally in 2017, around 558,000 cases were rifampicin-resistant of which 82% were multidrug-resistant (MDR) TB. In England, 5,102 cases were recorded of which 55 cases (1.8%) were MDR-TB. MDR-TB cases have worse outcomes and are a serious public health issue.Polymerase chain reaction (PCR) tests ...
Park, M, Satta, G, Kon, OM
openaire   +3 more sources

Explaining risk factors for drug-resistant tuberculosis in England and Wales: contribution of primary and secondary drug resistance [PDF]

, 2004
Drug-resistant tuberculosis can be transmitted (primary) or develop during the course of treatment (secondary). We investigated risk factors for each type of resistance.
Glynn, JR, Story, A, Hayward, AC, Watson, JM, Conaty, SJ, Drobniewski, FA   +5 more
core   +1 more source

Diagnosis and Interim Treatment Outcomes from the First Cohort of Multidrug-Resistant Tuberculosis Patients in Tanzania. [PDF]

, 2013
Kibong'oto National Tuberculosis Hospital (KNTH), Kilimanjaro, Tanzania. Characterize the diagnostic process and interim treatment outcomes from patients treated for multidrug-resistant tuberculosis (MDR-TB) in Tanzania.
Kumburu Happiness H., Ndusilo, N.D., Boeree, M.J., Kibiki, Gibson S, Mpagama Stellah G., Kumburu, Happiness H, Houpt, Eric R, Heysell, Scott K, Eric R Houpt, Boeree Martin J., Kisonga, Riziki M, Kibiki, G.S., Nora D Ndusilo, Jean Gratz, Ndusilo Nora D., Riziki M Kisonga, Boeree, Martin J, Lekule Isack A., Stellah G Mpagama, Martin J Boeree, Heysell, S.K., Kisonga Riziki M., Mpagama, Stellah G, Ndusilo, Nora D, Kumburu, H.H., Scott K Heysell, Lekule, Isack A, Gratz, J., Kisonga, R.M., Gratz, Jean, Kibiki Gibson S., Houpt, E.R., Gibson S Kibiki, Heysell Scott K., Mpagama, S.G., Lekule, I.A., Houpt Eric R., Isack A Lekule, Gratz Jean, Happiness H Kumburu   +39 more
core   +2 more sources

Programmatically selected multidrug-resistant strains drive the emergence of extensively drug-resistant tuberculosis in South Africa [PDF]

, 2013
South Africa shows one of the highest global burdens of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). Since 2002, MDR-TB in South Africa has been treated by a standardized combination therapy, which until 2010 included
Pillay, Manormoney, van Helden, Paul D., Nicolaas C. Gey van Pittius (173264), Paul D. van Helden (33594), Marlein E Bosman, Gagneux, Sebastien, Thomas C Victor, Manormoney Pillay (257769), Nicolaas C Gey van Pittius, Borna Müller (173253), Hayes, Cindy, Streicher, Elizabeth M., Andre Trollip (449922), Robin M Warren, Elizabeth M Streicher, Trollip, Andre, Violet N. Chihota (143307), Warren, Robin M., Bosman, Marlein E., Müller, Borna, Violet N Chihota, Cindy Hayes, Marisa Klopper (398815), Cindy Hayes (449923), Elizabeth M. Streicher (439727), Borna Müller, Paul D van Helden, Marlein E. Bosman (449924), Klopper, Marisa, Gerrit Coetzee, Sebastien Gagneux (149824), Chihota, Violet N., Andre Trollip, Marisa Klopper, Sebastien Gagneux, Gerrit Coetzee (296078), Victor, Thomas C., Manormoney Pillay, Coetzee, Gerrit, Gey van Pittius, Nicolaas C., Robin M. Warren (33593), Thomas C. Victor (185348)   +41 more
core   +2 more sources

Multidrug-resistant tuberculosis today [PDF]

Bulletin of the World Health Organization, 2012
The World Health Organization (WHO) and its partners have long conducted efforts to improve tuberculosis (TB) case surveillance and programme monitoring and evaluation. WHO’s 2011 report on global TB control1 provided the most reliable information ever generated on the burden of disease and death caused by TB and multidrug-resistant TB (i.e.
Matteelli, A., Centis, R., D'Ambrosio, L., Migliori, G. B.   +3 more
openaire   +4 more sources

Transmission of multidrug-resistant tuberculosis in the UK: a cross-sectional molecular and epidemiological study of clustering and contact tracing [PDF]

, 2014
BACKGROUND: Between 2000 and 2012 the number of multidrug-resistant (MDR) tuberculosis cases in the UK increased from 28 per year to 81 per year. We investigated the proportion of MDR tuberculosis cases arising from transmission in the UK and associated ...
Abubakar, Ibrahim, Anderson, Laura F, Brown, Timothy, Watson, JP, Abubakar, I, Tamne, Surinder, Mullarkey, C, Anderson, LF, Tamne, S, Zenner, D, Brown, T, Mullarkey, Catherine, Watson, John P, Zenner, Dominik   +13 more
core   +1 more source

SHORT-TERM CHEMOTHERAPY REGIMEN OF MULTIDRUG-RESISTANT TUBERCULOSIS IN THE KYRGYZ REPUBLIC

Паёми Сино, 2018
Objective: To study the clinical course of tuberculosis (TB) with multiple drug resistance (MDR) in the treatment of short-term courses recommended by the WHO.
E.V. ZHDANOVA, G.K. TURDUMAMBETOVA
doaj   +1 more source